Edwards Lifesciences Corporation (EW) — Analyst outlook / Analyst consensus target is. Based on 48 analyst ratings, the consensus is bullish — 32 Buy, 16 Hold.
The consensus price target is $96.38 (low: $87.00, high: $110.00), representing an upside of 23.2% from the current price $78.20.
Analysts estimate Earnings Per Share (EPS) of $2.57 and revenue of $5.80B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $6.98 vs est $2.57 (beat +171.8%). 2025: actual $1.84 vs est $2.60 (missed -29.1%). Analyst accuracy: 48%.
EW Stock — 12-Month Price Forecast
$96.38
▲ +23.25% Upside
Average Price Target
Based on 48 Wall Street analysts offering 12-month price targets for Edwards Lifesciences Corporation, the average price target is $96.38, with a high forecast of $110.00, and a low forecast of $87.00.
The average price target represents a +23.25% change from the last price of $78.20.
Highest Price Target
$110.00
Average Price Target
$96.38
Lowest Price Target
$87.00
EW Analyst Ratings
Buy
Based on 48 analysts giving stock ratings to Edwards Lifesciences Corporation in the past 3 months
EPS Estimates — EW
48%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $6.98
vs Est $2.57
▲ 63.2% off
2025
Actual $1.84
vs Est $2.60
▼ 41.1% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — EW
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $5.440B
vs Est $5.795B
▼ 6.5% off
2025
Actual $6.068B
vs Est $6.044B
▲ 0.4% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
